BioStock: Spago Nanomedical’s CEO about the plans for the coming twelve months
Summarising the first half of 2021 for Spago Nanomedical, several milestones have been reached, including the successful capital raise and the change of trading venue to Nasdaq First North in March. Spago Nanomedical is now advancing, focusing on the cancer treatment project Tumorad and the diagnostics project SpagoPix, which is currently undergoing a clinical trial. BioStock spoke with CEO Mats Hansen about the current projects and what he expects to achieve within the next twelve months.
Read the full interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/